Skip to main content

Table 2 Outcomes for the 84 virologically suppressed HIV-infected patients entered in this study

From: Efficacy and safety of switching from nevirapine immediate-release twice daily to nevirapine extended-release once daily in virologically suppressed HIV-infected patients: a retrospective cohort study in Taiwan

  All NVP-XR NVP-IR P
N = 84 N = 35 N = 49
Ability to maintain a virological response, n (%) 71 (84.5) 29 (82.9) 42 (85.7) 0.72
Reason for treatment failure
 Death, n (%) 0 (0.0) 0 (0.0) 0 (0.0)  
 Switch to other cART due to adverse effect or other cause, n (%) 4 (4.8) 2 (5.7) a 2 (4.1) 1.00
 Virological failure, n (%) 2 (2.4) 1 (2.9) 1 (2.0) 1.00
 Loss to follow-up, n (%) 6 (7.1) 3 (8.6) 4 (8.1) 1.00
Virological blip, n (%) 6 (7.1) 4 (11.4) 2 (4.1) 0.23
Change from baseline in CD4 T-cells, mean cells/mm3 (± SD) 14 (122) 23 (171) 76 (127) 0.33
  1. cART combined antiretroviral therapy, NVP nevirapine, SD standard deviation
  2. aOne patient in the NVP-XR group discontinued NVP-XR because of insufficient supply of the drug